Abstract
The neuroepigenome, i.e., the epigenome of the nervous system, has become interesting for therapeutics in the last years due to widespread availability of dedicated drugs. A pivotal role for neuroepigenetics is certainly implied, both in physiology and pathology, by the highly dynamic structural and functional rearrangements that constantly occur into the nervous system, globally known as plasticity. Moreover, the idea that the pathophysiology of several neuropsychiatric disorders might involve epigenetic mechanisms is increasingly taking place due to accumulating experimental data and by the evidence of a synergistic interaction between genes and environment beneath most sporadic forms of these diseases. In this paper we will review the available evidence on the use of epigenome-modifying drugs in the field of neuropsychiatry, shortly describing for each disease the underlying assumptions of an epigenetic dysregulation.
Keywords: Neuroepigenome, histone deacetylase, DNA methylation, neuropsychiatric disorders.
Current Pharmaceutical Design
Title:Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome
Volume: 20 Issue: 11
Author(s): Lucio Tremolizzo, Virginia Rodriguez-Menendez, Elisa Conti, Chiara Paola Zoia, Guido Cavaletti and Carlo Ferrarese
Affiliation:
Keywords: Neuroepigenome, histone deacetylase, DNA methylation, neuropsychiatric disorders.
Abstract: The neuroepigenome, i.e., the epigenome of the nervous system, has become interesting for therapeutics in the last years due to widespread availability of dedicated drugs. A pivotal role for neuroepigenetics is certainly implied, both in physiology and pathology, by the highly dynamic structural and functional rearrangements that constantly occur into the nervous system, globally known as plasticity. Moreover, the idea that the pathophysiology of several neuropsychiatric disorders might involve epigenetic mechanisms is increasingly taking place due to accumulating experimental data and by the evidence of a synergistic interaction between genes and environment beneath most sporadic forms of these diseases. In this paper we will review the available evidence on the use of epigenome-modifying drugs in the field of neuropsychiatry, shortly describing for each disease the underlying assumptions of an epigenetic dysregulation.
Export Options
About this article
Cite this article as:
Tremolizzo Lucio, Rodriguez-Menendez Virginia, Conti Elisa, Zoia Paola Chiara, Cavaletti Guido and Ferrarese Carlo, Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome, Current Pharmaceutical Design 2014; 20 (11) . https://dx.doi.org/10.2174/13816128113199990535
DOI https://dx.doi.org/10.2174/13816128113199990535 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in the Development of 14-Alkoxy Substituted Morphinans as Potent and Safer Opioid Analgesics
Current Medicinal Chemistry Biomarkers of Angiogenesis and their Role in Patient Selection for Antiangiogenic Therapy
Current Angiogenesis (Discontinued) Meet Our Editorial Board Member
Current Cancer Therapy Reviews Peptide Therapeutics in Neurodegenerative Disorders
Current Medicinal Chemistry Novel Strategies to Discover Effective Drug Targets in Metabolic and Immune Therapy for Glioblastoma
Current Cancer Drug Targets Stem Cells: Their Role in Breast Cancer Development and Resistance to Treatment
Current Pharmaceutical Biotechnology Autophagy: Molecular Mechanisms and their Implications for Anticancer Therapies
Current Cancer Drug Targets Advances in Helper-Dependent Adenoviral Vector Research
Current Gene Therapy Opioid Receptor Interacting Proteins and the Control of Opioid Signaling
Current Pharmaceutical Design Lipid based Nanocapsules: A Multitude of Biomedical Applications
Current Pharmaceutical Biotechnology The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review
Current Cancer Drug Targets Astrocytes as an HIV Reservoir: Mechanism of HIV Infection
Current HIV Research Meet Our Associate Editor
Current Bioactive Compounds A Glance Over the Cannabinoid Machinery to Design New Anti- Angiogenic Compounds
Mini-Reviews in Medicinal Chemistry Endocytosis, Intracellular Traffic and Fate of Cell Penetrating Peptide Based Conjugates and Nanoparticles
Current Pharmaceutical Design Safety and Utilization of Blood Components as Therapeutic Delivery Systems
Current Pharmaceutical Biotechnology Repurposed Drugs in Metabolic Disorders
Current Topics in Medicinal Chemistry Therapeutic Potential of Curcumin in the Treatment of Glioblastoma Multiforme
Current Pharmaceutical Design TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges
Reviews on Recent Clinical Trials Targeting Cytotoxic Conjugates of Somatostatin, Luteinizing Hormone- Releasing Hormone and Bombesin to Cancers Expressing Their Receptors: A “Smarter” Chemotherapy
Current Pharmaceutical Design